2026-04-13T02:00:41Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4747212025-07-29T22:47:02Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Waszczuk-Gajda, Anna author Penack, Olaf author Sbianchi, Giulia author Koster, Linda author Blaise, Didier author Reményi, Péter author Russell, Nigel author Ljungman, Per author Trneny, Marek author Mayer, Jiri author Iacobelli, Simona author Kobbe, Guido author Scheid, Christof author Apperley, Jane author Touzeau, Cyrille author Lenhoff, Stig author Jantunen, Esa author Anagnostopoulos, Achilles author Paris, Laura author Browne, Paul author Thieblemont, Catherine author Schaap, Nicolaas author Sierra, Jorge author Yakoub-Agha, Ibrahim author Garderet, Laurent author Styczynski, Jan author Schoemans, Helene author Moiseev, Ivan author Duarte, Rafael author Peric, Zinaida author Montoto, Silvia author van Biezen, Anja author Mikulska, Malgorzata author Aljurf, Mahmoud author Ruutu, Tapani author Kröger, Nicolaus author Morris, Curly Morris author Koenecke, Christian author Schoenland, Stefan author Basak, Grzegorz author Universitat Autònoma de Barcelona author 2022 Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short-and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0-100 days, 101 days-1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4-108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1-7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3-5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies. Autologous stem cell transplantation in multiple myeloma Complications Multiple myeloma Complications of Autologous Stem Cell Transplantation in Multiple Myeloma : Results from the CALM Study